Render Target: STATIC
Render Timestamp: 2025-03-14T10:34:58.867Z
Commit: a619ae74f66dae0f27639e88da12bcf600e46428
XML generation date: 2025-03-07 13:20:21.190
Product last modified at: 2025-02-26T08:00:54.255Z
Cell Signaling Technology Logo
View Featured Offers >>
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
  1. Products /
  2. Primary Antibodies /
  3. CD44 v6 (C44Mab-9) Mouse mAb
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CD44 v6 (C44Mab-9) Mouse mAb #99618

Filter:
  • WB
  • IHC
  • F

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 200-220
    Source/Isotype Mouse IgG1 kappa
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunohistochemistry (Paraffin) 1:50 - 1:200
    Flow Cytometry (Live) 1:100 - 1:400

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CD44 v6 (CD44Mab-9) Mouse mAb recognizes endogenous levels of total CD44 protein containing the variant v6 exon.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the human CD44 variant v3-v10. This antigen has been further characterized as corresponding to residues surrounding Phe404 of human CD44 protein, within the CD44 variant v6 exon.

    Background

    CD44 is a type I transmembrane glycoprotein that mediates cell-cell and cell-matrix interaction through its affinity for hyaluronic acid (HA) and possibly through other parts of the extracellular matrix (ECM). CD44 is highly polymorphic, possesses a number of alternative splice variants and undergoes extensive post-translational modifications (1,2). Increased surface levels of CD44 are characteristic of T cell activation, and expression of the protein is upregulated during the inflammatory response. Research studies have shown that interactions between CD44 and HER2 are linked to an increase in ovarian carcinoma cell growth (1-3). CD44 interacts with ezrin, radixin, and moesin (ERM), linking the actin cytoskeleton to the plasma membrane and the ECM (4-6). CD44 is constitutively phosphorylated at Ser325 in resting cells. Activation of PKC results in phosphorylation of Ser291, dephosphorylation of Ser325, disassociation of ezrin from CD44, and directional motility (4).

    Human CD44 consists of 19 exons, of which 10 are expressed in the standard isoform (CD44s) and all other isoforms. The nine variant exons (v2-v10) inserted between the constant regions via alternative splicing are the source of CD44 heterogeneity, and can dramatically alter the cell-adhesion properties of CD44-expressing cells (7-10). Expression of CD44 isoforms containing exon v6 is associated with metastasis and poor clinical outcomes in colorectal cancer, osteosarcoma, breast cancer, head and neck squamous cell carcinoma, endometriosis, and pancreatic carcinoma (11-16).

    Among pancreatic ductal adenocarcinomas (PDAC) cell lines, those that highly express CD44v, including CD44 v6, exhibit an epithelial or MET phenotype, express E-cadherin, and have an increased growth rate (9). Conversely, PDAC cells that highly express CD44s exhibit a mesenchymal phenotype, have high gemcitabine resistance, and co-express proteins associated with EMT transition, including vimentin and ZEB-1 (9). In vivo, PDAC cells have the ability to switch between expression of these CD44 isoforms in response to chemotherapy, demonstrating the importance of CD44-targeted therapies for treatment of some cancers (9).
    1. Goodison, S. et al. (1999) Mol. Pathol. 52, 189-196.
    2. Cichy, J. and Puré, E. (2003) J. Cell Biol. 161, 839-843.
    3. Bourguignon, L.Y. et al. (1997) J. Biol. Chem. 272, 27913-27918.
    4. Legg, J.W. et al. (2002) Nat. Cell Biol. 4, 399-407.
    5. Yonemura, S. et al. (1998) J. Cell Biol. 140, 885-895.
    6. Tsukita, S. et al. (1994) J. Cell Biol. 126, 391-401.
    7. Ejima, Ryo, et al. (2023) Int J Mol Sci. 24(4):4007
    8. Chen, C. et al. (2018) J Hematol Oncol 11, 64.
    9. Zhao, S. et al. (2016) Clin Cancer Res 22, 5592-5604.
    10. Rudzki, Z. and Jothy, S. (1997) Mol Pathol 50, 57-71.
    11. Ma, L. et al. (2019) Cell Death Dis 10, 30.
    12. Liang, S. et al. (2024) Future Oncol 20, 1799-1806.
    13. Kaufmann, M. et al. (1995) Lancet 345, 615-9.
    14. Athanassiou-Papaefthymiou, M. et al. (2014) Int J Immunopathol Pharmacol 27, 337-49.
    15. Knudtson, J.F. et al. (2020) F S Sci 1, 188-194.
    16. Li, Z. et al. (2014) Diagn Pathol 9, 79.

    Database Links

    UniProt ID: P16070


    Entrez-Gene Id: 960


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.